| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046150997 |
| P356 | DOI | 10.1038/BJC.1992.369 |
| P932 | PMC publication ID | 1977984 |
| P698 | PubMed publication ID | 1358168 |
| P5875 | ResearchGate publication ID | 21797878 |
| P2093 | author name string | Philip P | |
| Carmichael J | |||
| Harris AL | |||
| Stuart NS | |||
| Kirk J | |||
| Houlbrook S | |||
| Tonkin K | |||
| Lien EA | |||
| P2860 | cites work | Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype | Q30909909 |
| A human cell line from a pleural effusion derived from a breast carcinoma | Q34207627 | ||
| A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants | Q34488592 | ||
| Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients | Q35984149 | ||
| Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry | Q35986320 | ||
| Reversal of multidrug resistance | Q37614214 | ||
| Preclinical studies with toremifene as an antitumor agent. | Q37865123 | ||
| Pharmacology of drugs that alter multidrug resistance in cancer | Q37969138 | ||
| The biochemistry of P-glycoprotein-mediated multidrug resistance | Q38364215 | ||
| Genetic and biochemical characterization of multidrug resistance | Q39402232 | ||
| Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients | Q41328786 | ||
| Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. | Q41445387 | ||
| Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression | Q41633673 | ||
| Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine | Q41690863 | ||
| Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein | Q41715788 | ||
| Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line | Q41724047 | ||
| Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. | Q41734532 | ||
| Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein | Q41739204 | ||
| Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. | Q41740564 | ||
| P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies | Q41881467 | ||
| Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. | Q42249927 | ||
| Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance | Q44253536 | ||
| Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil | Q45178839 | ||
| Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. | Q50886497 | ||
| Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. | Q50904345 | ||
| Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. | Q50906237 | ||
| Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. | Q54279436 | ||
| Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine | Q54307235 | ||
| Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. | Q54346288 | ||
| Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. | Q54356862 | ||
| Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. | Q54367285 | ||
| Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate | Q54390461 | ||
| Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. | Q54419426 | ||
| Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens. | Q54424007 | ||
| Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. | Q54497909 | ||
| Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma | Q67026274 | ||
| Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells | Q67325558 | ||
| Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide | Q67843573 | ||
| Factors contributing to adriamycin sensitivity in human xenograft tumors: the relationship between expression of the MDR1, GST-pi and topoisomerase II genes and tumor sensitivity to adriamycin | Q67845165 | ||
| Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile | Q68285921 | ||
| Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography | Q69206808 | ||
| Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment | Q69579611 | ||
| Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil | Q70721995 | ||
| Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers | Q71356163 | ||
| Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II | Q72397901 | ||
| Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines | Q72561176 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytotoxicity | Q246181 |
| tamoxifen | Q412178 | ||
| etoposide | Q418817 | ||
| P304 | page(s) | 833-839 | |
| P577 | publication date | 1992-11-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines | |
| P478 | volume | 66 |
| Q36976172 | AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment |
| Q40774302 | Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial |
| Q37226553 | Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature |
| Q47925224 | Cell cycle regulation of human pancreatic cancer by tamoxifen |
| Q40464085 | Clinical Studies with Modulators of Multidrug Resistance |
| Q41906544 | Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites |
| Q28534675 | Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling |
| Q45082362 | Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells |
| Q41924929 | Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells |
| Q40240897 | Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. |
| Q40747806 | Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells |
| Q48497164 | High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma |
| Q58215297 | High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma |
| Q43707361 | High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma |
| Q28610020 | Human liver microsomal metabolism of paclitaxel and drug interactions |
| Q36080370 | Interaction of tamoxifen with the multidrug resistance P-glycoprotein. |
| Q40464073 | MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. |
| Q41498467 | Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo |
| Q41690629 | Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. |
| Q44365787 | Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies |
| Q71760918 | Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma |
| Q30274798 | Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer |
| Q41579366 | Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. |
| Q40879713 | Tamoxifen and ATP synergistically activate Cl- release by cultured bovine pigmented ciliary epithelial cells |
| Q40341146 | Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. |
| Q41935356 | Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? |
| Q40925894 | Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. |
| Q28084270 | Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications |
| Q43503919 | Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. |
Search more.